Expression profiling for bladder cancer: Strategies to uncover prognostic factors

Expert Review of Anticancer Therapy

Volumn 10, Issue 12, 2010, Pages 1945-1954

  Bartsch, Georg ^a   Mitra, Anirban P ^a   Cote, Richard J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

gene expression profiling; global approach; microarray; multimarker analysis; pathway specific approach; urothelial carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROTEIN P53; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; BLADDER CANCER; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

CARCINOMA, TRANSITIONAL CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 78649676657     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.131     Document Type: Review

References (69)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Heney NM. Natural history of superfcial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19(3), 429-433 (1992).
3. Urinary bladder. In: AJCC Cancer Staging Manual. Greene FL, Page DL, Fleming ID et al. (Eds). Springer-Verlag, NY, USA, 367-374 (2002).
4. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol. 166(2), 490-493 (2001).
5. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol. 163(6), 1693-1696 (2000).
6. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classifcation of urothelial neoplasms: practical choices for patient care. J. Urol. 168(3), 968-972 (2002).
7. Bol MG, Baak JP, Buhr-Wildhagen S et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J. Urol. 169(4), 1291-1294 (2003).
8. Mitra A P, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 4, 251-285 (2009).
9. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25(6), 563-571 (2007).
10. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin. Genitourin. Cancer 5(1), 67-77 (2006).
11. Mitra AP, Cote RJ. Searching for novel therapeutics and targets: insights from clinical trials. Urol. Oncol. 25(4), 341-343 (2007).
12. George B, Datar RH, Wu L et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol. 25(34), 5352-5358 (2007).
13. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259-1264 (1994).
14. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst. 85(1), 53-59 (1993).
15. Serth J, Kuczyk MA, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superfcial transitional cell carcinoma of the bladder. Br. J. Cancer 71(1), 201-205 (1995).
16. Mitra AP, Lin H, Cote RJ, Datar RH. Biomarker profling for cancer diagnosis, prognosis and therapeutic management. Natl Med. J. India 18(6), 304-312 (2005).
17. WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst. 90(14), 1072-1079 (1998).
18. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int. 96(1), 7-12 (2005).
19. Simon R, Struckmann K, Schraml P et al. Amplifcation pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21(16), 2476-2483 (2002).
20. Sanchez-Carbayo M, Socci ND, Kirchoff T et al. A polymorphism in HDM2 (SNP309) associates with early onset in superfcial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin. Cancer Res. 13(11), 3215-3220 (2007).
21. Mitra A P, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identifcation. J. Clin. Oncol. 24(35), 5552-5564 (2006).
22. Mitra A P, Bartsch CC, Cote RJ. Strategies for molecular expression profling in bladder cancer. Cancer Metastasis Rev. 28(3-4), 317-326 (2009).
23. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br. J. Cancer 71(4), 831-835 (1995).
24. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58(6), 1090-1094 (1998).
25. Chatterjee SJ, George B, Goebell PJ et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J. Pathol. 203(3), 762-770 (2004).
26. Perabo FG, Kamp S, Schmidt D et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br. J. Cancer 84(10), 1330-1338 (2001).
27. Yamana K, Bilim V, Hara N et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br. J. Cancer 93(5), 544-551 (2005).
28. Wolf HK, Stober C, Hohenfellner R, Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol. 22(5), 328-336 (2001).
29. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A et al. BCL-2, TP53 and BAX protein expression in superfcial urothelial bladder carcinoma. Cancer Lett. 250(2), 292-299 (2007).
30. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superfcial bladder cancer: an update on etiology, molecular development, classifcation, and natural history. Rev. Urol. 10(1), 31-43 (2008).
31. Fitzgerald JM, Ramchurren N, Rieger K et al. Identifcation of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J. Natl Cancer Inst. 87(2), 129-133 (1995).
32. Birkhahn M, Mitra AP, Williams AJ et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profles. Eur. Urol. 57(1), 12-20 (2010).
33. Xia G, Kumar SR, Hawes D et al. Expression and signifcance of vascular endothelial growth factor receptor 2 in bladder cancer. J. Urol. 175(4), 1245-1252 (2006).
34. Mitra AP, Almal AA, George B et al. The use of genetic programming in the analysis of quantitative gene expression profles for identifcation of nodal status in bladder cancer. BMC Cancer 6, 159 (2006).
35. Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 7(3), 329-330 (2000).
36. Mitra AP, Pagliarulo V, Yang D et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 27(24), 3929-3937 (2009).
37. Tiniakos DG, Mellon K, Anderson JJ, Robinson MC, Neal DE, Horne CH. c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. Br. J. Urol. 74(6), 757-761 (1994). (Pubitemid 24378078)
38. Yao HQ, Peng Y, Zhong ZZ, He HX, Li ZH. Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer. Di Yi Jun Yi Da Xue Xue Bao 24(2), 177-179 (2004).
39. Youssef RF, Mitra AP, Bartsch G Jr, Jones PA, Skinner DG, Cote RJ. Molecular targets and targeted therapies in bladder cancer management. World J. Urol. 27(1), 9-20 (2009).
40. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl Cancer Inst. 87(21), 1603-1612 (1995).
41. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol Med. 11, e26 (2009).
42. Theodoropoulos VE, Lazaris A, Sofras F et al. Hypoxia-inducible factor 1a expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46(2), 200-208 (2004).
43. Theodoropoulos VE, Lazaris AC, Kastriotis I et al. Evaluation of hypoxia-inducible factor 1a overexpression as a predictor of tumour recurrence and progression in superfcial urothelial bladder carcinoma. BJU Int. 95(3), 425-431 (2005).
44. Palit V, Phillips RM, Puri R, Shah T, Bibby MC. Expression of HIF-1a and Glut-1 in human bladder cancer. Oncol. Rep. 14(4), 909-913 (2005).
45. Crew JP, O'Brien T, Bradburn M et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superfcial bladder cancer. Cancer Res. 57(23), 5281-5285 (1997). (Pubitemid 27516364)
46. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J. Urol. 166(4), 1275-1279 (2001).
47. Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 89(3), 219-227 (1997).
48. Birkhahn M, Mitra A P, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev. Anticancer Ther. 7(12), 1717-1727 (2007).
49. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22(6), 1007-1013 (2004).
50. Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014-1024 (2004).
51. Rosenblatt R, Jonmarker S, Lewensohn R et al. Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol. 29(5), 311-322 (2008).
52. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol. 20(4), 445-459 (2007).
53. Shariat SF, Karakiewicz PI, Ashfaq R et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112(2), 315-325 (2008).
54. Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 8(2), 128-136 (2007).
55. Rosser CJ, Liu L, Sun Y et al. Bladder cancer-associated gene expression signatures identifed by profling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 18(2), 444-453 (2009).
56. Sanchez-Carbayo M, Socci ND, Lozano JJ et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol. 163(2), 505-516 (2003).
57. Modlich O, Prisack HB, Pitschke G et al Identifying superfcial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profles. Clin. Cancer Res. 10(10), 3410-3421 (2004).
58. Dyrskjøt L, Thykjaer T, Kruhoffer M et al Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33(1), 90-96 (2003).
59. Blaveri E, Simko JP, Korkola JE et al Bladder cancer outcome and subtype classifcation by gene expression. Clin. Cancer Res. 11(11), 4044-4055 (2005).
60. Dyrskjøt L, Kruhoffer M, Thykjaer T et al Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classifcation. Cancer Res. 64(11), 4040-4048 (2004).
61. Dyrskjøt L, Zieger K, Kruhoffer M et al A molecular signature in superfcial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 11(11), 4029-4036 (2005).
62. Wild PJ, Herr A, Wissmann C et al. Gene expression profling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin. Cancer Res. 11(12), 4415-4429 (2005).
63. Kim WJ, Kim EJ, Kim SK et al. Predictive value of progression-related gene classifer in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).
64. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defning molecular profles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778-789 (2006).
65. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjøt L, Ørntoft TF. Gene expression profling of noninvasive primary urothelial tumours using microarrays. Br. J. Cancer 93 (10), 1182-1190 (2005).
66. Takata R, Katagiri T, Kanehira M et al Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profling. Clin. Cancer Res. 11(7), 2625-2636 (2005).
67. Als AB, Dyrskjøt L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13(15 Pt 1), 4407-4414 (2007).
68. Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21), 8302-8309 (2009).
69. Zieger K. High throughput molecular diagnostics in bladder cancer-on the brink of clinical utility. Mol. Oncol. 1(4), 384-394 (2008).